Skip to content

Efficacy and Safety of FF-31501 in Meniscus Tear Patients

A Phase 3 Single-arm Multicenter Study of FF-31501 in Meniscus Tear Patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05777967
Enrollment
18
Registered
2023-03-21
Start date
2023-01-01
Completion date
2025-12-31
Last updated
2024-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniscus Injury

Brief summary

A single-arm, multi-center study to verify that knee joint function at 52 weeks after injection of FF-31501 is better than at screening in patients with meniscus tear who are eligible for meniscectomy .

Interventions

BIOLOGICALhuman autologous synovial stem cells

A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy

Sponsors

FUJIFILM Toyama Chemical Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients with suspected meniscal flap tear 2. Patients with knee pain 3. Patients with one or more of the following symptoms * Feeling stuck in the knee・Instability of the knee * Knee range of motion impairment * Knee joint edema 4. Other

Exclusion criteria

1. Patients with poor knee alignment 2. Patients who underwent meniscus surgery or platelet rich plasma therapy 3. Patients with or history of knee ligament injury 4. Diabetic patients with poor glycemic control 5. Patients with the following complications and poor general condition * Severe cardiovascular disease * Severe liver disease * Severe renal dysfunction * Severe anemia・uncontrolled mental illness * Other diseases for which sudden change or worsening of symptoms can be expected during study participation 6. Patients who are pregnant or possibly pregnant and/or breast-feeding, or patients planning to become pregnant during the study period 7. Other

Design outcomes

Primary

MeasureTime frameDescription
Lysholm scoreScreening up to 52 weeksIt consists of items that measure: pain, instability, locking, swelling, limp, stair climbing, squatting, and need for support. Lowest and highest scores are 0 and 100 (better), respectively.

Secondary

MeasureTime frameDescription
Arthroscopic assessment of the meniscusMeniscus repair up to 52 weeksThe structure and function of the repaired meniscus will be assessed in terms of the presence, stability, and smoothness of the meniscus by arthroscopic imaging and MRI.
Knee injury and osteoarthritis outcome score (KOOS)Screening up to the Day before injection,4,12,24 and 52 weeksThe KOOS consists of five subscales; Pain, other symptoms, function in daily living (ADL), function in sport and recreation (Sport/Rec) and knee related quality of life (QOL). Lowest and highest scores are 0 and 100 (better), respectively.
Numerical Rating Scale (NRS)Screening up to the Day before injection,4,12,24 and 52 weeksNRS consists of an 11-point scale to evaluate current knee pain where no pain is indicated by '0', and the worst pain imaginable by '10'.
Kellgren LawrenceScreening up to 24 and 52 weeksThe Kellgren and Lawrence system is a common method of classifying the severity of osteoarthritis (OA) using five grades.

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026